Dispatches from CPhI

Gene therapy to drive viral and biologics market, says SAFC

This content item was originally published on www.biopharma-reporter.com, a William Reed online publication.

By Gareth Macdonald

- Last updated on GMT

Related tags: Medicine, Biotechnology

Gene therapy to drive viral and biologics market, says SAFC
SAFC Pharma has added extra viral and biologics capacity at its California plant in a $12m project that allows it to take projects from the lab to commercial scale.

The expansion includes two manufacturing suites that feature disposable bioreactor technologies to support the development and production of viral vaccines and viral therapeutics.

SAFC Pharma business development and marketing director David Backer spoke with in-PharmaTechnologist at CPhI in Madrid, Spain, explaining that the firm expects gene therapy to be the key driver for this type of contract manufacturing offering.

Validation work at the facility is under and SAFC Pharma expects to begin manufacturing operations by the end of the year.

Related news

Show more

Related products

show more

LACTIUM®: dairy bioactive to soothe your pet

LACTIUM®: dairy bioactive to soothe your pet

Ingredia | 12-Oct-2021 | Infographic

Lactium® gives you the chance to better meet your pet’s needs for a more harmonious life together. Lactium® acts on the brain and has no side-effects,...

Facilities: Lexington, KY USA

Facilities: Lexington, KY USA

Piramal Pharma Solutions | 23-Aug-2021 | Insight Guide

The Piramal Pharma Solutions facility in Lexington, KY USA is a fully integrated site which offers analytical, formulation development, and manufacturing...

Related suppliers

Follow us


View more